Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease

✍ Scribed by Tomoyuki Uchiyama; Ryuji Sakakibara; Tatsuya Yamamoto; Takashi Ito; M Chiharu Yamaguchi; Yusuke Awa; Masashi Yano; Mitsuru Yanagisawa; Makoto Kobayashi; Yoshinori Higuchi; Tomohiko Ichikawa; Tomonori Yamanishi; Takamichi Hattori; Satoshi Kuwabara

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 67 KB
• Volume: 24
• Category: Article
• ISSN: 0885-3185
• DOI: 10.1002/mds.22840

✦ Synopsis

Abstract

To evaluate the effects of bromocriptine on bladder function in Parkinson's disease (PD) patients and compare these effects with those of (L‐dopa). We recruited 8 patients with PD. Urodynamic study (UDS) was performed before and 1 hour after administering 100 mg L‐dopa/decarboxylase inhibitor (DCI) and 2.5 hours after administering 7.5 mg bromocriptine. After the bromocriptine administration, urinary urgency aggravated. UDS revealed a decreased bladder volume at which detrusor overactivity (DO) was initiated, a decreased bladder volume at first sensation of bladder filling (FSV) (P < 0.05), an increased maximum Watts Factor value (WFmax) (detrusor contractility), a decreased Abrams‐Griffiths (AG) number (urethral obstruction), and a decreased postvoid residual (PVR) (P < 0.01). Similarly, after the L‐dopa administration, urinary urgency aggravated. UDS revealed an aggravated DO (P < 0.05), a decreased FSV and bladder capacity (P < 0.01, 0.05), an increased WFmax (P < 0.05), an increased AG number, and a decreased PVR (P < 0.01). A single dose of bromocriptine proved to exacerbate urinary urgency and DO in the storage phase, and improve bladder emptying through increased detrusor contractility and decreased bladder outlet obstruction, within hours. With the exception of bladder outlet obstruction, these effects of bromocriptine are similar to the effects of L‐dopa, albeit slightly less pronounced. © 2009 Movement Disorder Society